This site is intended for health professionals only

Drug approval in von Willebrand disease


Grifols has received approval from the FDA to market Alphanate (antihaemophilic factor/von Willebrand factor complex [human]) for the treatment of congenital von Willebrand disease (VWD) in connection with surgery or other invasive procedures.

The drug is indicated for the prevention and control of bleeding in patients with factor VIII deficiency. It is also indicted for surgical and/or invasive procedures in patients with VWD, except type 3 patients undergoing major surgery, in whom desmopressin is either ineffective or contraindicated.

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine